Neocardon (Atenolol)

Atenolol works by selectively blocking β1‑adrenergic receptors in the heart. This inhibition reduces the influence of adrenaline and noradrenaline, leading to slower heart rate, decreased contractility, and lower cardiac output, which together lower blood pressure and myocardial oxygen demand.

The dose of Neocardon is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the appropriate strength, frequency, and any necessary adjustments, following current clinical guidelines and patient‑specific factors.

Safety data for atenolol during pregnancy and lactation are limited. It is generally classified as a drug to be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as atenolol can be excreted in breast milk.

To order Neocardon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Atenolol is a cardio‑selective (β1‑specific) beta blocker, offering fewer respiratory side effects than non‑selective agents such as propranolol. Compared with newer agents like carvedilol, atenolol has a shorter half‑life and lacks additional α‑blocking activity, making it suitable for patients needing pure β1 antagonism.

Neocardon tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Neocardon is taken orally, usually with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, heart block, bronchospasm in patients with asthma or COPD, and masking of hypoglycemia symptoms in diabetic individuals. Patients should seek immediate medical attention if they experience fainting, severe shortness of breath, or signs of an allergic reaction.

Atenolol is contraindicated in patients with known hypersensitivity to the drug, those with severe bradycardia, second‑ or third‑degree atrioventricular block, and patients with uncompensated heart failure. Caution is also advised for individuals with severe asthma, chronic obstructive pulmonary disease, or significant renal impairment.